| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 22, 2017The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.
22 Mar 2017 KING OF PRUSSIA, Pa — 22 March 2017 Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied Data show up to 40% of HAE...
-
Mar 1, 2017PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy
01 Mar 2017 KING OF PRUSSIA, Pa — 01 March 2017 Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy...
-
Feb 14, 2017FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition
14 Feb 2017 KING OF PRUSSIA, Pa — 14 February 2017 Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the...
-
Jan 9, 2017- CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A
09 Jan 2017 MARBURG, Germany — 09 January 2017 CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A The therapy has been specifically designed for greater...
-
Jan 5, 2017
05 Jan 2017 CAMBRIDGE, MA — 05 January 2017 Momenta to receive $50 million upfront license fee and up to 4550 million in potential milestone payments from CSL Momenta to host a conference call...